Experience of Using a Combined Expectorant in Community-acquired Pneumonia in Preschool Children

Authors

  • Ю. В. Марушко Bogomolets National Medical University
  • Т. В. Гищак Bogomolets National Medical University

DOI:

https://doi.org/10.30841/2307-5112.4.2020.217968

Keywords:

pneumonia, children, treatment, Askoril

Abstract

Acute pneumonia in preschool children often requires the use of combined drugs that affect cough. One of them is a combination of bromhexine, guaifenesin and salbutamol, which has proven itself in school-age children and adults. However, there is insufficient data on the use of such combination in children.

The objective: of our observation was to evaluate the clinical efficacy and safety of Askoril Expectorant therapy in children 2–7 years with acute community-acquired pneumonia.

Materials and methods. We have summarized the experience of treatment of 30 children aged 2–7 years, suffering from community-acquired pneumonia of moderate severity. Ascoril Expectorant was added to antibiotic therapy for 9–12 days. The general condition of patients, severity of cough, shortness of breath, sputum secretion, monitoring of side effects, heart rate, systolic and diastolic pressure were measured. Tolerability of the drug was studied according to clinical observations and using a ten-point visual-analog scale.

Results. All children before treatment had difficulty coughing up sputum. By the 2-3rd day of treatment, the cough became moist. Symptoms of nocturnal cough disappeared on the 5th–6th day of treatment, daytime – significantly decreased by the 6th–7th day of observation. Clinical signs of focal changes in the lungs persisted in all patients on 3–5 days of combination therapy and were absent in most patients within 10 days of treatment. On the third day of treatment the intensity of cough decreased from 2.53 to 1.07 points (p<0.001). On the fifth day of treatment the intensity of cough decreased by 2.9 times compared with the data at the beginning of therapy, on the tenth day – by 5.9 times. Good tolerability (8–10 points) was observed in 43.3 % of children, in others – satisfactory. No child had poor tolerability.

Conclusions. The inclusion in the complex treatment of patients with community-acquired pneumonia of the combined mucoactive drug Askoril Expectorant leads to rapid relief of the disease and the achievement of an effective mucoregulatory effect with good tolerability of the drug.

Author Biographies

Ю. В. Марушко, Bogomolets National Medical University

Yurii V. Marushko,

Head of Department of Pediatrics at the Institute of Postgraduate Education

Т. В. Гищак, Bogomolets National Medical University

Tetiana V. Hyshchak,

Department of Pediatrics at the Institute Postgraduate Education

References

Геппе Н.А., Селиверстова Н.А., Утюшева М.Г. (2011) Современные методы лечения кашля при острых респираторных заболеваниях у детей «Эффективная фармакотерапия. Пульмонология и оториноларингология». 2:46–54.

Григорьева Н.Ю. (2013) Оценка клинической эффективности и безопасности комбинированного препарата Аскорил у больных с коморбидной бронхолегочной и сердечно-сосудистой патологией. РМЖ. 26:1475–1481.

Клячкина И.Л. (2012) Лечение кашля при ОРВИ и гриппе. РМЖ. 6:278–281.

Клячкина И.Л., Синопальников А.И. (2015) Фиксированные комбинации мукоактивных препаратов в программе лечения кашля. 1:74–82.

Клячкина И.Л., Дмитриев Ю.К. (2012) Лечение нетяжелых обострений хронической обструктивной болезни легких. Клин. Мед. 3:69–73.

Крамарьов С.О., Євтушенко В.В., Марков А.І. (2015) Досвід застосування комбінованого препарату Аскоріл при гострих респіраторних інфекціях у дітей. Здоровье ребенка. 4: (64):85–91.

Лапшин В.Ф., Уманець Т.Р. (2014) Муколітична терапія у дітей з рецидивним бронхітом. Перинатологія і педіатрія. 3(59):36–39.

Марушко Ю.В., Крамарев С.А., Марушко Т.В., Шеф Г.Г. (2017) Избранные вопросы детской пульмонологии (для семейных врачей). Киев:148.

Мизерницкий Ю.Л., Мельникова И.М. (2013) Муколитическая и отхаркивающая фармакотерапия у детей. М.: Медпрактика-М:66.

Настанова 00620. Пневмонія у дітей: http://guidelines.moz.gov.ua/documents/2918. id=ebm00620&format=pdf.

Нургожин Т.С., Гуляев А.Е., Ермекбаева Б.А., Жаугашева С.К., Абуова Г.Т., Ан Э.А. (2013) Результаты международного многоцентрового неинтервенционного клинического исследования эффективности и безопасности аскорила экспекторанта при лечении кашля, проведенного в республике Казахстан и в республике Узбекистан. Клин. Мед.6:50–55.

Перцева Т.А., Киреева Т.В., Кравченко Н.К. (2013) Кашель: патогенетически обоснованный выбор терапии. Ліки України. 6:50–56.

Синопальников А.И., Клячкина И.Л. (2013) Кашель М.: Медицинское информационное агентство: 151–152.

Титова Т.А. (2019) Ефективність і контроль лікування гострого кашлю Медична газета «Здоров’я України 21 сторіччя». 15-16:460–461.

Юдіна Л.В. Комбінована мукоактивна терапія: погляд пульмонолога. (2017) Ліки України. Medicine of Ukraine. 6 (212):16–20.

Prabhu Shankar S., Chandrashekharan S., Bolmall C.S., Baliga V. (2010) Efficacy, safety and tolerability of salbutamol + guaiphenesin + bromhexine (Ascoril) expectorant versus expectorants containing salbutamol and either guaiphenesin or bromhexine in productive cough: a randomised controlled comparative study. J Indian Med Assoc. 08 (5):313–320.

Shmeleva N.M. Use of the Mucoregulator Ascoril for Respiratory Diseases. Ter Arkh. 2012;84(10):86–90.

Published

2020-10-30

Issue

Section

Pediatrics